Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Neurology

• Publication date

  1991-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.41.2_Part_1.202PMID 1992362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of age at onset on progression and mortality in Parkinson's disease

  1989cited by this paper
• Is Parkinson's disease of early onset a separate disease entity?

  1989cited by this paper
• A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease

  1988cited by this paper
• Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems.

  1987cited by this paper
• Young onset Parkinson's disease

  1987cited by this paper
• Juvenile onset Parkinson's disease.

  1987cited by this paper
• Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism.

  1987cited by this paper
• Current Status of Levodopa Therapy in Idiopathic Parkinson's Disease

  1987cited by this paper
• Parkinson's disease: progression and mortality.

  1987cited by this paper
• Nosography of Parkinson's disease.

  1986cited by this paper
• L‐dopa long‐term treatment in Parkinson's disease

  1983cited by this paper
• Parkinsonism

  1967cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Le Journal Canadien Des Sciences Neurologiques New Data on the Genetics of Parkinson's Disease

  year unknowncited by this paper

• The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson’s disease: multicenter cross-sectional study

  2026cites this paper
• Neurobiochemical alterations in patients with idiopathic Parkinson's disease in sensorimotor cortex using 1H-MRS.

  2025cites this paper
• Early-Onset Parkinson’s Disease: Unique Features and Management Approaches

  2025cites this paper
• Opicapone in Parkinson's disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit.

  2025cites this paper
• Clinical progression of Parkinson's disease in the early 21st century: Insights from AMP-PD dataset

  2024cites this paper
• Early Levodopa-Induced Motor Complications in RAB39B X-Linked Parkinsonism

  2024cites this paper
• Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease

  2024cites this paper
• Dysregulation of tyrosinase activity: a potential link between skin disorders and neurodegeneration.

  2023cites this paper
• Comparison of UPDRS III score between young and late onset Parkinson disease after deep brain stimulation: A meta-analysis

  2023cites this paper
• Exploring the prescribing trends and factors affecting initial anti-parkinsonian drug selection in Korea: A nationwide population-based cohort study.

  2023cites this paper
• Parkinson’s Disease Non-Motor Subtypes Classification in a Group of Slovenian Patients: Actuarial vs. Data-Driven Approach

  2023cites this paper
• COMT inhibitor tolcapone represses the migration and invasion of trophoblast and results in preeclampsia-like phenotypes in mice

  2023cites this paper
• Shaping the course of early-onset Parkinson’s disease: insights from a longitudinal cohort

  2023cites this paper
• Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder

  2022cites this paper
• Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes.

  2022cites this paper
• Clinical differences between early-onset and mid-and-late-onset Parkinson's disease: Data analysis of the Hellenic Biobank of Parkinson's disease.

  2022cites this paper
• Non-motor symptoms fluctuations in patients with Parkinson's disease at the Clinical Hospital of Salvador, Bahia

  2022cites this paper
• Pharmacological management of Parkinson’s disease motor symptoms: update and recommendations from an expert

  2022cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?

  2021cites this paper
• Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)

  2021cites this paper
• Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson’s Disease

  2021cites this paper
• Opicapone for the Treatment of Parkinson’s Disease "Off" Episodes: Pharmacology and Clinical Considerations

  2021cites this paper
• Neurosurgeons perspective on the shift towards earlier use of deep brain stimulation for parkinson disease

  2021cites this paper
• Real-world assessment of “OFF” episode–related healthcare resource utilization among patients with Parkinson’s disease in the United States

  2021cites this paper
• Deep Brain Stimulation and Treatment Outcomes of Young- and Late-Onset (≤55 Years) Parkinson's Disease: A Population-Based Study

  2021cites this paper
• Young Onset Parkinson’s Disease: A Modern and Tailored Approach

  2020cites this paper
• Overview of therapeutic drugs and methods for the treatment of Parkinson's disease.

  2020cites this paper
• The Risk Factors for the Wearing-Off Phenomenon in Parkinson's Disease

  2020cites this paper
• Structural characterization and neuroprotective effect of a polysaccharide from Corydalis yanhusuo.

  2020cites this paper
• Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease

  2020cites this paper
• Young-onset Parkinson's disease: Its unique features and their impact on quality of life.

  2019cites this paper
• Gami–Chunggan Formula Prevents Motor Dysfunction in MPTP/p-Induced and A53T α-Synuclein Overexpressed Parkinson’s Disease Mouse Model Though DJ-1 and BDNF Expression

  2019cites this paper
• Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.

  2019cites this paper
• A comprehensive Movement and Motion training program improves mobility in Parkinson’s disease

  2019cites this paper
• Parkinson's Disease

  2019cites this paper
• Subtyping of Parkinson’s Disease - Where Are We Up To?

  2019cites this paper
• Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia

  2018cites this paper
• Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease

  2018cites this paper
• Stem Cell Roles and Applications in Genetic Neurodegenerative Diseases

  2018cites this paper
• The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?

  2018cites this paper
• Animal Models of Pathological Aging

  2018cites this paper
• Cardiac Sympathetic Denervation Can Predict the Wearing-off Phenomenon in Patients with Parkinson Disease

  2018cites this paper
• Salusin-β mediate neuroprotective effects for Parkinson's disease.

  2018cites this paper
• Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia

  2018cites this paper
• Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

  2018cites this paper
• The role of serotonergic and dopaminergic mechanisms and their interaction in Levodopa-induced dyskinesias

  2018cites this paper
• Characteristic Motor and Nonmotor Symptoms Related to Quality of Life in Drug-Naïve Patients with Late-Onset Parkinson Disease

  2018cites this paper
• Levodopa-induced dyskinesia: clinical features, incidence, and risk factors

  2018cites this paper
• Underutilization of deep brain stimulation for Parkinson’s disease? A survey on possible clinical reasons

  2017cites this paper
• The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study

  2017cites this paper
• The Genetics of Parkinson Disease.

  2017cites this paper
• Risk factors for levodopa-induced dyskinesia in Parkinson’s disease patients

  2017cites this paper
• Adverse drug reaction to antiparkinson agents in Idiopathic Parkinson Disease: a prospective observational study in a Movement Disorder outpatient clinic

  2017cites this paper
• Psychosocial difficulties in patients with Parkinson’s disease

  2017cites this paper
• Polestriding Intervention Improves Gait and Axial Symptoms in Mild to Moderate Parkinson Disease.

  2017cites this paper
• Identification phénoménologique des substrats neurobiologiques de la relation impulsivité / compulsivité : approche transnosographique

  2017cites this paper
• Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease

  2017cites this paper
• Cognitive and Neuropsychiatric Features of Early Parkinson's Disease

  2017cites this paper
• Hallmarks of Clinical Aspects of Parkinson's Disease Through Centuries.

  2017cites this paper
• Motor Complications of Dopaminergic Medications in Parkinson's Disease

  2017cites this paper
• Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications

  2016cites this paper
• D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia

  2016influential citation
• Neuroprotective effects of honokiol against beta-amyloid-induced neurotoxicity via GSK-3β and β-catenin signaling pathway in PC12 cells.

  2016cites this paper
• An update on the diagnosis and treatment of Parkinson disease

  2016cites this paper
• “Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease

  2016cites this paper
• Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist

  2016cites this paper
• Early-onset vs. Late-onset Parkinson’s disease: A Clinical-pathological Study

  2015influential citation
• Rôle de Narp dans le développement des dyskinésies induites par la L-DOPA

  2015cites this paper
• Systems Regulating and Inducing Dopaminergic Cell Death in Parkinson’s Disease: an Analysis of Signalling Associated with Parkinson's Disease Models

  2015cites this paper
• Modern treatment in Parkinson’s disease, a personal approach

  2015cites this paper
• Asian perspectives on the recognition and management of levodopa ‘wearing-off’ in Parkinson’s disease

  2015cites this paper
• Treatment strategies in early and advanced Parkinson disease.

  2015cites this paper
• Non-motor symptoms in Indian patients with Parkinson’s disease

  2015cites this paper
• Differential regulation of caspase-2 in MPP⁺-induced apoptosis in primary cortical neurons.

  2015cites this paper
• Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson’s Disease Modifier Genes

  2015cites this paper
• L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.

  2015cites this paper
• Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats

  2014influential citation
• Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease

  2014cites this paper
• Isorhynchophylline Treatment Improves the Amyloid-β-Induced Cognitive Impairment in Rats via Inhibition of Neuronal Apoptosis and Tau Protein Hyperphosphorylation

  2014cites this paper
• Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease

  2014influential citation
• Fasciculation and elongation protein zeta‐1 (FEZ1) expression in reactive astrocytes in a rat model of Parkinson's disease

  2014cites this paper
• Epidemiology of Levodopa-Induced Dyskinesia

  2014cites this paper
• Idiopathisches Parkinson-Syndrom

  2014cites this paper
• Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo patients with Parkinson's disease

  2014cites this paper
• L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.

  2014cites this paper
• Managing Uncertainty in Young-Onset Parkinson's Disease

  2014cites this paper
• Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan

  2014cites this paper
• Striatal cholinergic interneuron regulation and circuit effects

  2014cites this paper
• Brittle Dyskinesia Following STN but not GPi Deep Brain Stimulation

  2014cites this paper
• Drug-Induced Chorea

  2014cites this paper
• Continuous Drug Delivery in Parkinson’s Disease

  2013cites this paper
• Chapter 11 – Drugs for Neuropsychiatric Disorders

  2013cites this paper
• Comparison the neuropreotective effect of Cortex Phellodendri chinensis and Cortex Phellodendri amurensis against beta-amyloid-induced neurotoxicity in PC12 cells.

  2013cites this paper
• Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.

  2013cites this paper
• Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson's Disease

  2013cites this paper
• Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.

  2013cites this paper
• Parkinson-Syndrom(e) – Neue Konzepte für eine sich ausbreitende Erkrankung?

  2013cites this paper
• Risk Factors for Falls in Home Care and Long-Term Care Settings: A Focus on Dementia and Parkinson's Disease

  2013cites this paper
• Treatment of depression and anxiety in Parkinson’s Disease

  2013cites this paper